Neovii is a global leader in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology/oncology. The company's lead product, Grafalon®, has been making a significant impact for over 30 years, being utilized to treat patients and widely available in more than 40 countries worldwide. It has gained approval for use in immunosuppressive therapies for prevention of graft-versus-host disease in stem cell transplantation, prevention and treatment of rejection in solid organ transplantation, and in the treatment of aplastic anemia. Founded in 2003 and headquartered in Switzerland, Neovii operates within the Biotechnology and Health Care industries. The company's established presence in the global market signifies a strong track record and potential for continued growth and innovation. While specific details regarding the last investment and associated investors are not currently available, Neovii's extensive experience and widespread usage of Grafalon® position it as an attractive venture for potential investment within the biotechnology and healthcare sectors.
There is no investment information
No recent news or press coverage available for Neovii .
We care about your data, and we'd love to use cookies make your experience better.